Caprock Group LLC Takes Position in Kenvue Inc. $KVUE

Caprock Group LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 63,662 shares of the company’s stock, valued at approximately $1,033,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Stratos Wealth Partners LTD. lifted its holdings in shares of Kenvue by 61.8% during the third quarter. Stratos Wealth Partners LTD. now owns 22,664 shares of the company’s stock valued at $368,000 after purchasing an additional 8,658 shares during the last quarter. Providence Capital Advisors LLC raised its position in shares of Kenvue by 3.1% during the third quarter. Providence Capital Advisors LLC now owns 132,086 shares of the company’s stock valued at $2,144,000 after buying an additional 3,912 shares during the last quarter. Versor Investments LP increased its stake in Kenvue by 2.8% in the 3rd quarter. Versor Investments LP now owns 26,016 shares of the company’s stock worth $422,000 after acquiring an additional 716 shares during the last quarter. Winslow Asset Management Inc. boosted its stake in Kenvue by 1.7% during the third quarter. Winslow Asset Management Inc. now owns 171,950 shares of the company’s stock worth $2,791,000 after buying an additional 2,843 shares during the period. Finally, ProShare Advisors LLC raised its position in shares of Kenvue by 7.5% in the 3rd quarter. ProShare Advisors LLC now owns 7,766,831 shares of the company’s stock valued at $126,056,000 after purchasing an additional 540,182 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. Edward Jones lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Evercore set a $18.00 price target on shares of Kenvue in a research report on Tuesday, October 28th. Barclays increased their price target on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Finally, Canaccord Genuity Group reaffirmed a “hold” rating and issued a $15.00 price objective (down from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. Four analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus price target of $19.46.

Kenvue Price Performance

KVUE stock opened at $18.70 on Monday. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The stock’s 50 day moving average is $17.38 and its two-hundred day moving average is $17.70. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17. The company has a market capitalization of $35.82 billion, a PE ratio of 24.93 and a beta of 0.59.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date is Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is presently 110.67%.

Insider Buying and Selling

In related news, Director Jeffrey C. Smith bought 3,200,000 shares of the business’s stock in a transaction on Friday, December 12th. The shares were bought at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the purchase, the director owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. This represents a 13.27% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.17% of the stock is currently owned by insiders.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.